Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Enanta Pharmaceuticals, Inc. (ENTA : NSDQ)
 
 • Company Description   
Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.

Number of Employees: 131

 
 • Price / Volume Information   
Yesterday's Closing Price: $6.98 Daily Weekly Monthly
20 Day Moving Average: 134,242 shares
Shares Outstanding: 21.38 (millions)
Market Capitalization: $149.21 (millions)
Beta: 0.84
52 Week High: $17.24
52 Week Low: $4.09
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.80% -9.33%
12 Week 36.86% 15.12%
Year To Date 21.39% 13.68%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
4 KINGSBURY AVENUE
-
WATERTOWN,MA 02472
USA
ph: 617-607-0800
fax: 617-607-0530
ir@enanta.com http://www.enanta.com
 
 • General Corporate Information   
Officers
Jay R. Luly - President and Chief Executive Officer and Director
Paul J. Mellett - Chief Financial and Administrative Officer
Bruce L.A. Carter - Director
Mark G. Foletta - Director
Yujiro S. Hata - Director

Peer Information
Enanta Pharmaceuticals, Inc. (CORR.)
Enanta Pharmaceuticals, Inc. (RSPI)
Enanta Pharmaceuticals, Inc. (CGXP)
Enanta Pharmaceuticals, Inc. (BGEN)
Enanta Pharmaceuticals, Inc. (GTBP)
Enanta Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29251M106
SIC: 2834
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/04/25
Share - Related Items
Shares Outstanding: 21.38
Most Recent Split Date: (:1)
Beta: 0.84
Market Capitalization: $149.21 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.05 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.97 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.59
Price/Cash Flow: -
Price / Sales: 2.31
EPS Growth
vs. Year Ago Period: 27.89%
vs. Previous Quarter: -0.95%
Sales Growth
vs. Year Ago Period: -12.48%
vs. Previous Quarter: -11.99%
ROE
06/30/25 - -
03/31/25 - -79.83
12/31/24 - -75.53
ROA
06/30/25 - -
03/31/25 - -26.65
12/31/24 - -27.30
Current Ratio
06/30/25 - -
03/31/25 - 5.29
12/31/24 - 5.47
Quick Ratio
06/30/25 - -
03/31/25 - 5.29
12/31/24 - 5.47
Operating Margin
06/30/25 - -
03/31/25 - -149.57
12/31/24 - -157.57
Net Margin
06/30/25 - -
03/31/25 - -149.57
12/31/24 - -157.57
Pre-Tax Margin
06/30/25 - -
03/31/25 - -153.41
12/31/24 - -159.88
Book Value
06/30/25 - -
03/31/25 - 4.38
12/31/24 - 5.24
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 1.42
12/31/24 - 1.19
 

Powered by Zacks Investment Research ©